Immunotargeting and eradication of orthotopic melanoma using a chemokine-enhanced DNA vaccine

Gene Therapy

Volumn 20, Issue 9, 2013, Pages 939-948

  Igoucheva, O ^a   Grazzini, M ^b   Pidich, A ^c   Kemp, D M ^a   Larijani, M ^a   Farber, M ^a   Lorton, J ^a   Rodeck, U ^a   Alexeev, V ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF FLORENCE   (Italy)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

chemokines; DNA vaccination; immunotherapy; leukocyte recruitment; melanoma

Indexed keywords

CANCER VACCINE; DNA VACCINE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; SECONDARY LYMPHOID TISSUE CHEMOKINE; TRP2 PADRE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; DNA MODIFICATION; IMMUNE RESPONSE; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR REGRESSION;

ANIMALIA; MUS;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CHEMOKINE CCL20; CHEMOKINE CCL21; GENETIC THERAPY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; SKIN; SKIN NEOPLASMS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA;

EID: 84883851607     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2013.17     Document Type: Article

References (52)

1. Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 2009; 58: 1-14.
2. Goff SL, Smith FO, Klapper JA, Sherry R, Wunderlich JR, Steinberg SM et al. Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J Immunother 2010; 33: 840-847.
3. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114: 535-546.
4. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009; 21: 233-240.
5. Cameron F, Whiteside G, Perry C. Ipilimumab: first global approval. Drugs 2011; 71: 1093-1104.
6. Gajewski TF. Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy. Pigment Cell Melanoma Res 2010; 23: 580-581.
7. Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P. Ipilimumab. Nat Rev 2011; 10: 411-412.
8. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009; 58: 823-830.
9. Wolchok JD, Weber JS, Hamid O, Lebbe C, Maio M, Schadendorf D et al. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun 2010; 10: 9.
10. Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003; 9: 1284-1290. (Pubitemid 36418378)
11. Slingluff Jr. CL, Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C et al. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 2007; 13: 6386-6395. (Pubitemid 350075028)
12. Talebi T, Weber JS. Peptide vaccine trials for melanoma: preclinical background and clinical results. Sem Cancer Biol 2003; 13: 431-438. (Pubitemid 38156135)
13. Hisada M, Yoshimoto T, Kamiya S, Magami Y, Miyaji H, Yoneto T et al. Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT. Cancer Gene Ther 2004; 11: 280-288. (Pubitemid 41184347)
14. Kirk CJ, Hartigan-O'Connor D, Nickoloff BJ, Chamberlain JS, Giedlin M, Aukerman L et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res 2001; 61: 2062-2070. (Pubitemid 32692028)
15. Sharma S, Stolina M, Luo J, Strieter RM, Burdick M, Zhu LX et al. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 2000; 164: 4558-4563. (Pubitemid 30238052)
16. Mule JJ. Dendritic cell-based vaccines for pancreatic cancer and melanoma. Ann N Y Acad Sci 2009; 1174: 33-40.
17. Terando A, Roessler B, Mule JJ. Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector. Cancer Gene Ther 2004; 11: 165-173. (Pubitemid 38280519)
18. Novak L, Igoucheva O, Cho S, Alexeev V. Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication. Mol Cancer Ther 2007; 6: 1755-1764. (Pubitemid 46954052)
19. Ferrone CR, Perales MA, Goldberg SM, Somberg CJ, Hirschhorn-Cymerman D, Gregor PD et al. Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains. Clin Cancer Res 2006; 12: 5511-5519. (Pubitemid 44497268)
20. Facco M, Baesso I, Miorin M, Bortoli M, Cabrelle A, Boscaro E et al. Expression and role of CCR6/CCL20 chemokine axis in pulmonary sarcoidosis. J Leukocyte Biol 2007; 82: 946-955. (Pubitemid 47511055)
21. Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 2007; 204: 2803-2812. (Pubitemid 350179551)
22. Ichimura M, Hiratsuka K, Ogura N, Utsunomiya T, Sakamaki H, Kondoh T et al. Expression profile of chemokines and chemokine receptors in epithelial cell layers of oral lichen planus. J Oral Pathol Med 2006; 35: 167-174.
23. Guo JH, Fan MW, Sun JH, Jia R. Fusion of antigen to chemokine CCL20 or CXCL13 strategy to enhance DNA vaccine potency. Int Immunopharmacol 2009; 9: 925-930.
24. Shih NY, Yang HY, Cheng HT, Hung YM, Yao YC, Zhu YH et al. Conditioning vaccination site with irradiated MIP-3alpha-transfected tumor cells enhances efficacy of dendritic cell-based cancer vaccine. J Immunother 2009; 32: 363-369.
25. Manzo A, Bugatti S, Caporali R, Prevo R, Jackson DG, Uguccioni M et al. CCL21 expression pattern of human secondary lymphoid organ stroma is conserved in inflammatory lesions with lymphoid neogenesis. Am J Pathol 2007; 171: 1549-1562. (Pubitemid 350158316)
26. Manzo A, Paoletti S, Carulli M, Blades MC, Barone F, Yanni G et al. Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur J Immunol 2005; 35: 1347-1359. (Pubitemid 40691416)
27. McDonald KG, McDonough JS, Wang C, Kucharzik T, Williams IR, Newberry RD. CC chemokine receptor 6 expression by B lymphocytes is essential for the development of isolated lymphoid follicles. Am J Pathol 2007; 170: 1229-1240. (Pubitemid 47339331)
28. Park JY, Jin DH, Lee CM, Jang MJ, Lee SY, Shin HS et al. CD4\+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8\+ T cells. J Immunother 2010; 33: 510-522.
29. Weber JS, Hua FL, Spears L, Marty V, Kuniyoshi C, Celis E. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J Immunother 1999; 22: 431-440. (Pubitemid 29488761)
30. BenMohamed L, Krishnan R, Auge C, Primus JF, Diamond DJ. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology 2002; 106: 113-121. (Pubitemid 34437884)
31. del Guercio MF, Alexander J, Kubo RT, Arrhenius T, Maewal A, Appella E et al. Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine 1997; 15: 441-448. (Pubitemid 27157695)
32. Wu A, Zeng Q, Kang TH, Peng S, Roosinovich E, Pai SI et al. Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer. Gene Therapy 2011; 18: 304-312.
33. Chan RC, Gutierrez B, Ichim TE, Lin F. Enhancement of DNA cancer vaccine efficacy by combination with anti-angiogenesis in regression of established subcutaneous B16 melanoma. Oncol Rep 2009; 22: 1197-1203.
34. Shields JD, Kourtis IC, Tomei AA, Roberts JM, Swartz MA. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science (New York, NY) 2010; 328: 749-752.
35. Richmond A, Yang J, Su Y. The good and the bad of chemokines/chemokine receptors in melanoma. Pigment Cell Melanoma Res 2009; 22: 175-186.
36. Flanagan K, Moroziewicz D, Kwak H, Horig H, Kaufman HL. The lymphoid chemokine CCL21 costimulates naive T cell expansion and Th1 polarization of non-regulatory CD4\+ T cells. Cell Immunol 2004; 231: 75-84. (Pubitemid 40775606)
37. Thompson ED, Enriquez HL, Fu YX, Engelhard VH. Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med 2010; 207: 1791-1804.
38. Chen YX, Man K, Ling GS, Chen Y, Sun BS, Cheng Q et al. A crucial role for dendritic cell (DC) IL-10 in inhibiting successful DC-based immunotherapy: superior antitumor immunity against hepatocellular carcinoma evoked by DC devoid of IL-10. J Immunol 2007; 179: 6009-6015.
39. Demangel C, Bertolino P, Britton WJ. Autocrine IL-10 impairs dendritic cell (DC)-derived immune responses to mycobacterial infection by suppressing DC trafficking to draining lymph nodes and local IL-12 production. Eur J Immunol 2002; 32: 994-1002. (Pubitemid 34428814)
40. Barath S, Aleksza M, Tarr T, Sipka S, Szegedi G, Kiss E. Measurement of natural (CD4\+CD25high) and inducible (CD4\+IL-10\+) regulatory T cells in patients with systemic lupus erythematosus. Lupus 2007; 16: 489-496. (Pubitemid 47242522)
41. Ohkusu-Tsukada K, Toda M, Udono H, Kawakami Y, Takahashi K. Targeted inhibition of IL-10-secreting CD25-Treg via p38 MAPK suppression in cancer immunotherapy. Eur J Immunol 2010; 40: 1011-1021.
42. Parkhurst MR, Fitzgerald EB, Southwood S, Sette A, Rosenberg SA, Kawakami Y. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res 1998; 58: 4895-4901. (Pubitemid 28503687)
43. Rangel-Moreno J, Moyron-Quiroz JE, Hartson L, Kusser K, Randall TD. Pulmonary expression of CXC chemokine ligand 13, CC chemokine ligand 19, and CC chemokine ligand 21 is essential for local immunity to influenza. Proc Natl Acad Sci USA 2007; 104: 10577-10582. (Pubitemid 47185707)
44. Reynolds SR, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D et al. HLAindependent heterogeneity of CD8\+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. J Immunol 1998; 161: 6970-6976. (Pubitemid 28562245)
45. Ghiorzo P, Pastorino L, Pizzichetta MA, Bono R, Queirolo P, Talamini R et al. CDKN2A and MC1R analysis in amelanotic and pigmented melanoma. Melanoma Res 2009; 19: 142-145.
46. Wankowicz-Kalinska A, Mailliard RB, Olson K, Graham F, Edington H, Kirkwood JM et al. Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8\+ T cells in the lesional skin of a patient with melanoma-related depigmentation. Melanoma Res 2006; 16: 165-174. (Pubitemid 44101951)
47. Campbell JJ, Haraldsen G, Pan J, Rottman J, Qin S, Ponath P et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 1999; 400: 776-780. (Pubitemid 29399540)
48. Curran MA, Montalvo W, Yagita H, JP Allison. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010; 107: 4275-4280.
49. Kroumpouzos G, Urabe K, Kobayashi T, Sakai C, Hearing VJ. Functional analysis of the slaty gene product (TRP2) as dopachrome tautomerase and the effect of a point mutation on its catalytic function. Biochem Biophys Res Comm 1994; 202: 1060-1068.
50. Skinner PJ, Daniels MA, Schmidt CS, Jameson SC, Haase AT. Cutting edge: in situ tetramer staining of antigen-specific T cells in tissues. J Immunol 2000; 165: 613-617. (Pubitemid 30484723)
51. Jimenez M, Maloy WL, Hearing VJ. Specific identification of an authentic clone for mammalian tyrosinase. J Biol Chem 1989; 264: 3397-3403. (Pubitemid 19063397)
52. Jimenez M, Tsukamoto K, Hearing VJ. Tyrosinases from two different loci are expressed by normal and by transformed melanocytes. J Biol Chem 1991; 266: 1147-1156. (Pubitemid 21907238)